Table 1

Clinical characteristics of patients with active RA and RA in remission in our and in Midtbø's study

Cioffi et al3Midtbø et al1p Value
Active RA
SDAI > 3.3
(n=162)
Remission RA
SDAI≤3.3
(n=44)
Active RA
SDAI > 3.3
(n=78)
Remission RA
SDAI≤3.3
(n=41)
Age (years)62.5 (11.3)58.4 (12.7)60.7 (11.7)62.1 (11.2)NS
Women, n (%)131 (81)30 (69)60 (77)31 (76)NS
Body mass index (kg/m2)25.7 (4.9)25.3 (3.6)25.5 (4.8)25.6 (4.2)NS
Current smoking, n (%)75 (46)14 (31)19 (25)6 (15)<0.01
Diabetes, n (%)16 (10)4 (8)11 (14)1 (3)<0.05
Total serum cholesterol (mmol/L)5.6 (1.0)5.5 (1.1)5.5 (1.2)6.2 (1.3)NS
Use of statins, n (%)52 (32)8 (19)15 (19)3 (7)<0.01
ESR (mm/hour), median (IQR)25 (20)18 (16)13.5 (8.8–26.3)10 (6.5–16)NS
CRP (mg/L), median (IQR)5.4 (9.0)2.1 (4.0)5 (2–11.3)2 (1.0–3.5)NS
Systolic blood pressure (mm Hg)135 (18)131 (17)136 (22)131 (20)NS
Diastolic blood pressure (mm Hg)83 (9)85 (11)80 (10)79 (10)NS
Hypertension, n (%)91 (56)15 (35)47 (60)14 (0.34)NS
Medically treated hypertensive patients, n (%)87 (54)15 (35)31 (66)5 (36)NS
RA disease duration (years)16.2 (11.4)14.3 (11.5)16.8 (2.1)17.2 (1.9)NS
RF positive, n (%)110 (68)14 (32)43 (63)16 (39)NS
Anti-CCP positive, n (%)104 (64)18 (40)42 (62)17 (42)NS
SDAI score, median (IQR)13.9 (9.2)1.5 (1.1)7.7 (5.1–12.2)1.8 (1.2–2.3)<0.001
CDAI score, median (IQR)13.3 (8.9)1.3 (1)6.6 (4.7–10.9)1.4 (1.0–2.0)<0.001
DMARDs, n (%)133 (82)39 (89)55 (71)19 (46)<0.05
Methotrexate, n (%)79 (49)20 (46)26 (33)13 (32)<0.05
TNFi, n (%)104 (64)25 (56)22 (28)7 (17)<0.01
Prednisolone, n (%)107 (66)15 (33)24 (31)12 (29)<0.01
  • p Values refer to both active versus active RA and remission versus remission RA patients.

  • Data are given as mean (SD) unless otherwise stated.

  • Anti-CCP, anti-cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; NS, not significant; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; TNFi, tumour necrosis factor inhibitor.